Shenzhen Yuanxing Biomedical Technology

Shenzhen Yuanxing Biomedical Technology is a Chinese biotechnology company specializing in the development and manufacturing of gene therapy products and viral vector-based vaccines. The company is most notable for its involvement with Gendicine, the world's first gene therapy product to receive regulatory approval, which utilizes a recombinant adenovirus to deliver the p53 tumor suppressor gene. Yuanxing operates large-scale GMP manufacturing facilities for viral vectors and provides contract manufacturing services for global partners. Their research focus extends to oncolytic viruses and recombinant vaccines for infectious diseases, positioning them as a key player in the Chinese biopharmaceutical infrastructure.